

7th INTERNATIONAL CONFERENCE ON MEDICAL & HEALTH SCIENCES

July 06-08, 2023

Ordu, Türkiye



EDITOR

Assist. Prof. Dr. Yeliz KAŞKO ARICI

ISBN: 978-625-7720-92-2

WEB: www.ispecongress.org/saglik



7th INTERNATIONAL CONFERENCE ON MEDICAL & HEALTH SCIENCES

July 06-08, 2023

Ordu, Türkiye

THE PROCEEDINGS BOOK

EDITOR

Assist. Prof. Dr. Yeliz KAŞKO ARICI

All rights of this book belong to ISPEC. Without permission can't be duplicate or copied.

Authors are responsible both ethically and juridically

ISPEC Publications – 2023 ©

Issued: 30.07.2023

ISBN: 978-625-7720-92-2

Bu Kitabın Tüm Hakları ISPEC Yayınevi'ne aittir.
Yazarlar etik ve hukuki olarak eserlerden sorumludurlar.

ISPEC Yayınevi – 2023 ©

Yayın Tarihi: 30.07.2023

ISBN: 978-625-7720-92-2

CONFERENCE ID

CONFERENCE TITLE

7th INTERNATIONAL CONFERENCE ON MEDICAL & HEALTH SCIENCES

DATE and PLACE

July 06-08, 2023 / Ordu – TÜRKİYE

ORGANIZATION

ISPEC INSTITUTE
Ordu University

HONORARY PRESIDENT OF THE CONGRESS

Prof. Dr. Ali AKDOĞAN

CHAIRMAN OF CONGRESS

Assist. Prof. Dr. Yeliz KAŞKO ARICI

ORGANISING COMMITTEE

Prof. Dr. Niyazi TAŞÇI

COORDINATOR

Gönül EDEŞLER
Neslihan BALCI

NUMBER of ACCEPTED PAPERS - 595

NUMBER of REJECTED PAPERS - 33

PARTICIPANTS COUNTRY

Türkiye (290), Albania (3), Algeria (19), ABD (1), Australia (2), Belarus (1), Benin (2), Brazil (4), Bulgaria (4), China (1), Georgia (25), Germany (7), Greece (1), India (61), Indonesia (3), Iran (15), Iraq (1), Israel (1), Italy (2), Kosovo (9), Malaysia (5), Morocco (19), México (1), Nigeria (36), Pakistan (28), Palestine (2), Philippines (1), Poland (1), Portugal (3), Romania (6), Russia (14), Sarajevo (1), Saudi Arabia (2), Serbia (3), Spain (1), Sri Lanka (1), Tunisia (5), Ukraine (7), United Kingdom (1), USA (1), Uzbekistan (1), Vietnam (5)

7th INTERNATIONAL CONFERENCE ON MEDICAL & HEALTH SCIENCES

July06-08, 2023 / Ordu, Türkiye
(THE PROCEEDINGS BOOK)

[https:// www.ispecongress.org/saglik](https://www.ispecongress.org/saglik)

ORGANIZING BOARD

Prof. Dr. Ahmet KAYA
Prof. Dr. Dilek KARAKUŞ
Prof. Dr. Hakan KORKMAZ
Prof. Dr. Saime ŞAHİNÖZ
Prof. Dr. Tülin BAYRAK
Assoc. Prof. Dr. Abdullah Alper ŞAHİN
Assoc. Prof. Dr. Ali ASLAN
Assoc. Prof. Dr. Ali AYGÜN
Assoc. Prof. Dr. Ali YILMAZ
Assoc. Prof. Dr. Mustafa Kerem ÇALGIN
Assoc. Prof. Dr. Mürüvvet AKÇAY ÇELİK
Assoc. Prof. Dr. Ömer KARAMAN
Assoc. Prof. Dr. Seda KESKİN
Assoc. Prof. Dr. Ülkü KARAMAN
Assoc. Prof. Dr. Yasemin KAYA
Assist. Prof. Dr. Yeliz KAŞKO ARICI
Assist. Prof. Dr. Aybegüm KALYONCU AYÇENK
Assist. Prof. Dr. Ceren YAPAR GÜMÜŞ
Assist. Prof. Dr. Çağrı DOĞAN
Assist. Prof. Dr. Deniz DENİZ ÖZTURAN
Assist. Prof. Dr. Fatma ETGÜ
Assist. Prof. Dr. Gonca GÜLBAY
Assist. Prof. Dr. Hatice HANCI
Assist. Prof. Dr. İlker COŞKUN
Assist. Prof. Dr. Mevlüt KELEŞ
Assist. Prof. Dr. Muhammet DEĞERMENCİ
Assist. Prof. Dr. Tuba GÜL
Assist. Prof. Dr. Selen KARAOĞLANOĞLU

SCIENCE AND ADVISORY BOARD

- Prof. Dr. Ayşe Canan YAZICI GÜVERCİN- Izmir Tinaztepe University
Prof. Dr. Cemil ÇOLAK- Inonu University
Prof. Dr. Erdal AĞAR- Giresun University
Prof. Dr. Handan ANKARALI- Istanbul Medeniyet University
Prof. Dr. Havva ERDEM- Ordu University
Prof. Dr. Hüseyin ŞAHİN- Giresun University
Prof. Dr. Nilay TAŞ- Ordu University
Prof. Dr. Orhan BAŞ- Samsun University
Prof. Dr. Serpil ŞENER - Inonu University
Prof. Dr. Siddık KESKİN- Van Yüzüncü Yıl University
Assoc. Prof. Dr. Abdullah ÇIRAKOĞLU- Ordu University
Assoc. Prof. Dr. Ahmet KARATAŞ- Ondokuz Mayıs University
Assoc. Prof. Dr. Aslıhan UZUN- Ordu University
Assoc. Prof. Dr. Atakan SAVRUN- University of Health Sciences
Assoc. Prof. Dr. Deha Denizhan KESKİN- Ordu University
Assoc. Prof. Dr. Emine YURDAKUL ERTÜRK- Ordu University
Assoc. Prof. Dr. Erdal BENLİ- Ordu University
Assoc. Prof. Dr. Hilal ALTAŞ- Ordu University
Assoc. Prof. Dr. Kaptamderya TAYFUR- Ordu University
Assoc. Prof. Dr. Mehmet Fatih KARAKUŞ- Ordu University
Assoc. Prof. Dr. Mustafa YENERÇAĞ- Samsun University
Assoc. Prof. Dr. Osman BEKTAŞ- Ordu University
Assoc. Prof. Dr. Pınar Naile ÖĞÜTEN- Samsun University
Assoc. Prof. Dr. Sercan ERGÜN- Ondokuz Mayıs University
Assoc. Prof. Dr. Şahin DİREKEL - Giresun University
Assist. Prof. Dr. Adem TOKPINAR- Ordu University
Assist. Prof. Dr. Bestegül ÇORUH AKYOL- Ordu University
Assist. Prof. Dr. Celali KURT- Ordu University
Assist. Prof. Dr. Didem ODABAŞI- Ordu University
Assist. Prof. Dr. Derya ÇIRAKOĞLU- Ordu University
Assist. Prof. Dr. Elif DOĞAN- Ordu University
Assist. Prof. Dr. Emine Serap YILMAZ- Ordu University
Assist. Prof. Dr. Güven AKÇAY- Hitit University
Assist. Prof. Dr. Halil YILMAZ- Ordu University
Assist. Prof. Dr. Hatice HANCI- Ordu University
Assist. Prof. Dr. Mehmet GÜZELİPEK- Ordu University
Assist. Prof. Dr. Muhammet ÖZBİLEN- Ordu University
Assist. Prof. Dr. Mücahit SEÇME- Ordu University
Assist. Prof. Dr. Nesrin ÇAĞLAYAN DUMAN- Ordu University
Assist. Prof. Dr. Onur YALÇIN- Ordu University

Assist. Prof. Dr. Semih TAN- Ordu University
Assist. Prof. Dr. Sibel TÜREDİ- Harran University
Assist. Prof. Dr. Swaroopa Rani Gurram- Mahavidhyapeetha College of Pharmacy
Assist. Prof. Dr. Türkan Mutlu YAR- Ordu University
Assist. Prof. Dr. Yağmur GÜNDÜZ- Ordu University
Assist. Prof. Dr. Yeliz KAŞKO ARICI- Ordu University
Dr. Ali IKRAM- Government College University Faisalabad
Dr. Almaz AHMEDOV- Bakü State University
Dr. Anatoliy LOGINOV - Ukraine Shevchenko Lugan National University
Dr. Ayslu B. SARSEKENOVA- Orleu National Development Institute
Dr. BOUKHATEM Mohamed Nadjib- Université Saad Dahlab Blida
Dr. Cholpon TOKTOSUNOVA- Rasulbekov Kyrgyz Economy University
Dr. Eze Ozoemena Emmanuel- University of Nigeria
Dr. Feda REHIMOV- Bakü State University
Dr. George RUDIC- Montreal Pedagogy Institute
Dr. Gülsen ŞENER- Başakşehir Çam and Sakura City Hospital
Dr. Kenes JUSUPOV- M. Tinisbaev Kazakh Vehicle Academy
Dr. Khan Nadezhda- E.A. Buketov Karaganda State University
Dr. Maha Hamdan ALANAZI- Riyad King Abdulaziz Technology Institute
Dr. Maira ESIMBOLOVA- Kazakhstan Narkhoz University
Dr. Maria LEONTIK- Macedonia Ishtib Gotse Delchev University
Dr. Maryam FARASAT- Ahvaz Jundishapur University of Medical Sciences
Dr. Mavlyanov ABDIGAPPAR- Kyrgyz Elaralık University
Dr. Meixia HUOU- Capital Normal University
Dr. Nazile Abdullazadeh- Azərbaycan Dövlət Pedaqoji University
Dr. Rovshan ALİYEV - Bakü State University
Dr. Zubera Naseem

EFFECTIVENESS OF NEW DIABETIC DRUG - SEMAGLUTIDE

Jenifer Alat Stephen

2-year Student of International Faculty of General Medicine, Tashkent Medical Academy

Mirkhamidova Sevara Mirmakhmudovna

Assistant of the Department of Public Health and Management, , Tashkent Medical Academy

ABSTRACT

A brand-new diabetic medication called semaglutide has been proven to be very successful in lowering blood sugar levels in persons with type 2 diabetes. It functions by imitating glucagon-like peptide-1 (GLP-1) hormone, which increases insulin production and suppresses hunger. Semaglutide can considerably lower HbA1c levels, a gauge of long-term blood sugar management, by up to 1.5%, according to clinical research. This is similar to other GLP-1 agonists like liraglutide and exenatide, however, it has the advantage of being administered once every seven days rather than daily. Semaglutide has been demonstrated to support weight reduction and minimize the risk of cardiovascular events in persons with type 2 diabetes in addition to its glucose-lowering benefits. This is probably because it enhances insulin sensitivity and suppresses hunger. Semaglutide does, however, have certain possible negative effects, much like any drug. These include pancreatitis, nausea, vomiting, and diarrhoea. In some people, it may also raise their chance of developing thyroid cancer and medullary thyroid carcinoma. It is not used to treat diabetic ketoacidosis, a dangerous disease that can arise if high blood sugar is not addressed, or type 1 diabetes, a condition in which the body does not make insulin and is unable to manage the quantity of sugar in the blood. When treating diabetics who require insulin, semaglutide injection is not substituted with insulin. In order to aid in weight loss in obese or overweight people who may also have high blood pressure, diabetes, or high cholesterol, semaglutide injection (Wegovy) is used in conjunction with a customised low-calorie, low-fat diet and exercise programme. In order to aid obese youngsters 12 years of age in losing weight, semaglutide injection (Wegovy) is also used in conjunction with a personalised low-calorie, low-fat diet and exercise programme. Semaglutide looks to be a potential new therapeutic choice for persons with type 2 diabetes who are having trouble maintaining blood sugar control, all things considered. It is a compelling substitute for other GLP-1 agonists because of its once-weekly dose and added advantages for weight loss and cardiovascular health. Once a week, semaglutide is given as a subcutaneous injection. It is offered in a variety of doses, from 0.25 mg to 1 mg. Depending on each person's response and tolerance, the dosage may need to be changed. Semaglutide can considerably enhance glycaemic control in persons with type 2 diabetes, according to clinical research. Additionally, it has been demonstrated that it helps persons with existing cardiovascular disease lose weight and lowers their chance of having a cardiovascular incident.

Semaglutide may result in adverse effects, much like any drug. The most frequent adverse effects include diarrhoea, constipation, diarrhoea, and nausea. Rarely, it could also result in thyroid cancer or pancreatitis. Semaglutide is a prescription drug that must only be used as directed by a medical professional. It is not advised to use.

KEYWORDS: Type 2 diabetes, GLP-1, Long-term blood sugar management, Weight reduction, Weekly dose, Cardiovascular health, 0.25 mg to 1mg, Thyroid cancer